New findings show a monoclonal antibody could target heroin addiction
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
List view / Grid view
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
UAB researchers have found that adding TBX20 to the reprogramming cocktail MGT 133 promoted cardiac reprograming.
A report has found that increased investment in drug discovery will help the demand for personalised medicine, encouraging the growth of the liquid handling market.
Scientists have developed a new method to study the proteins released by cells, which could lead to the development of new tools to track diseases including cancer.
The technology works by using an electric field to first capture a single cell in a microfluidic device, followed by applying a rotating electric field to rotate the trapped cell and then measuring the rotation speed.
Scientists have developed a new strategy to generate hair follicles in vitro with potential useful applications for treating hair loss, animal testing and drug screening.
Scientists shed light on how genetic architecture in human retina cells determine gene expression, tissue-specific function, and disease phenotype in blinding diseases.
Anti-inflammatory effects of niclosamide, observed in a new pre-clinical study, were due to inhibition of the inflammasome, a protein complex presented in the interior of defence cells.
A new AI model can accelerate drug discovery by accurately predicting human response to novel drug compounds.
Scripps scientists have mapped the protein structure of the Hepatitis C virus, paving the way for an effective vaccine.
H84T-BanLec has viral-blocking abilities by binding to polysaccharides that are present on the surface of the viruses.
A new implant that combines internal radiation and chemotherapy dissolved tumours in mice across multiple models.
Incannex Healthcare has completed a pre-IND meeting with the FDA for IHL-216A, a drug product for treatment of traumatic brain injury.
The findings provide insight into how genetics can make someone more susceptible to developing PTSD following trauma exposure.
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.